US Broker Ratings

CorMedix Inc. (CRMD) Stock Analysis: A Biotech Company with Over 100% Potential Upside

Investors seeking opportunities in the biotechnology sector might find CorMedix Inc. (NASDAQ: CRMD) an intriguing candidate. With a current market capitalization of $579.1 million, this healthcare..

GH Research PLC (GHRS) Stock Analysis: A Biotech Pioneer with a 146.95% Upside Potential

GH Research PLC (NASDAQ: GHRS), an emerging player in the biotechnology sector, has garnered significant attention from the investment community, primarily due to its promising drug..

Delcath Systems, Inc. (DCTH) Investor Outlook: Analyzing a 149.81% Potential Upside in the Healthcare Sector

Delcath Systems, Inc. (NASDAQ: DCTH), a prominent player in the healthcare sector specializing in medical devices, is capturing investor attention with its robust potential upside of..

Stoke Therapeutics, Inc. (STOK) Stock Analysis: Exploring a 37% Upside Potential

Stoke Therapeutics, Inc. (NASDAQ: STOK) has captured the attention of investors with its distinctive approach to treating severe genetic diseases. As a pioneering entity in the..

Altimmune, Inc. (ALT) Investor Outlook: Huge 259% Upside Potential as Analysts Bet Big on Biotech Breakthrough

For investors eyeing opportunities in the dynamic healthcare sector, Altimmune, Inc. (NASDAQ: ALT) presents a compelling case with its robust potential upside of 259.08%. This Gaithersburg,..

Arvinas, Inc. (ARVN) Stock Analysis: Navigating Potential Amidst Biotechnology Challenges

Arvinas, Inc. (NASDAQ: ARVN) is an intriguing company within the biotechnology sector, known for its innovative approach to drug development. With a market capitalization of approximately..

Auna SA (AUNA) Stock Analysis: 77% Potential Upside Captures Investor Attention

Auna SA (AUNA), a healthcare service provider with a significant footprint in Latin America, is garnering attention from investors due to its impressive potential upside of..

Amylyx Pharmaceuticals, Inc. (AMLX): Investor Outlook with 55.68% Potential Upside

Amylyx Pharmaceuticals, Inc. (AMLX), a clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, is making waves in the healthcare sector with its innovative approach to treating neurodegenerative..

Beta Bionics, Inc. (BBNX) Stock Analysis: Strong Buy Ratings Signal 117% Upside Potential

Beta Bionics, Inc. (NASDAQ: BBNX), a promising player in the medical devices sector, has garnered significant attention from investors due to its innovative solutions aimed at..

Anavex Life Sciences Corp. (AVXL)

❌ Error generating article: Server error: `POST https://api.openai.com/v1/chat/completions` resulted in a `502 Bad Gateway` response: 502 Bad Gateway 502 Bad Gateway clou (truncated…)

..

LENZ Therapeutics, Inc. (LENZ): A Biotech Stock with a Potential Upside of Over 267%

For investors with an eye on the biotechnology sector, LENZ Therapeutics, Inc. (NASDAQ: LENZ) presents an intriguing opportunity. Operating out of Solana Beach, California, this biopharmaceutical..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Unveiling a 136% Potential Upside Amidst Biotech Challenges

Vir Biotechnology, Inc. (NASDAQ: VIR) is a compelling name in the biopharmaceutical landscape, especially for investors seeking high-risk, high-reward opportunities. As a clinical-stage company, Vir Biotechnology..

Eton Pharmaceuticals (ETON): Exploring a 109% Potential Upside with a Strong Buy Consensus

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) has positioned itself as a compelling player in the healthcare sector, specifically within the niche of drug manufacturing for specialty and..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Through a 27% Potential Upside

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stands out in the biotechnology sector with its innovative contributions to drug and vaccine development. With a market capitalization of..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a Potential 286% Upside

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a name that continues to intrigue investors within the biotechnology sector due to its cutting-edge focus on cell therapies for..

Simulations Plus, Inc. (SLP) Stock Analysis: A Deeper Look at its 74% Potential Upside

Simulations Plus, Inc. (NASDAQ: SLP) stands at the intriguing intersection of healthcare and technology, specializing in cutting-edge software solutions for drug discovery and development. As a..

Arbutus Biopharma (ABUS) Stock Analysis: Unpacking the 56.51% Potential Upside in Biotech Investment

Arbutus Biopharma Corporation (NASDAQ: ABUS) is positioning itself as a compelling player in the biotechnology sector, with a notable focus on developing therapeutics for infectious diseases...

Neuropace, Inc. (NPCE) Stock Analysis: Exploring the 25.89% Potential Upside and Analyst Optimism

Investors looking for opportunities in the healthcare sector might find Neuropace, Inc. (NASDAQ: NPCE) a compelling addition to their portfolios. This U.S.-based medical device company, with..

Ardelyx, Inc. (ARDX) Stock Analysis: Evaluating a 110% Potential Upside with Strong Buy Ratings

Ardelyx, Inc. (NASDAQ: ARDX), a biotechnology company based in Waltham, Massachusetts, is catching the eye of investors with its significant potential upside and unanimous buy ratings..

AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring a 41.79% Potential Upside in Biotechnology

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company with a market capitalization of $1.34 billion, is capturing investor attention with its significant growth potential in the..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds